7.1 Sinusitis Higher use 58% of Negligible (15%) in prescriptions private use (restricted to cities, and ordered with Acute URTI infections patients one or more (14%) resistant to with repeats Otitis amoxicillin) COPD or (often for (10%) asthma COPD, Skin and sinusitis or wound bronchitis). infections Wide (~10%) variation between practices in repeats for URTI Roxithromycin 3.4 URTI (30%) Higher use 50% of Negligible (general in older prescriptions private use. Lower benefit) patients, written with Private respiratory and repeat. prescriptions tract infections patients Repeats ordered for (13%) with more courses of Bronchitis COPD or common for longer (12%) asthma. COPD, duration than Higher use tonsillitis, PBS courses in Victoria bronchitis or and major sinusitis. cities Wide variation in repeat prescribing across practices Doxycycline 3.3 PBS/RPBS Higher use 50% of 14% private (general use: acne in prescriptions use. Private benefit, (16%), had repeat prescriptions restricted for sinusitis (14%) (commonly more likely to some for acne or have longer Private use: indications) inner COPD) duration of travel (74%) regional treatment areas, and patients with COPD or asthma Azithromycin 0.7 PBS/RPBS Highest 7% of 42% private (restricted use: use in PBS/RPBS use benefit) Chlamydia prescriptions infections and 18% of (55%); ear, Higher use private eye, in Western prescriptions
(restricted to infections resistant to amoxicillin) 7.1 Sinusitis (15%) Acute URTI (14%) Otitis (10%) Skin and wound infections (~10%) Higher use in cities, and patients with COPD or asthma 58% of prescriptions ordered with one or more repeats (often for COPD, sinusitis or bronchitis). Wide variation between practices in repeats for URTI Negligible private use Roxithromycin (general benefit) 3.4 URTI (30%) Lower respiratory tract infections (13%) Bronchitis (12%) Higher use in older patients, and patients with COPD or asthma. Higher use in Victoria and major cities 50% of prescriptions written with repeat. Repeats more common for COPD, tonsillitis, bronchitis or sinusitis. Wide variation in repeat prescribing across practices Negligible private use. Private prescriptions ordered for courses of longer duration than PBS courses Doxycycline (general benefit, restricted for some indications) 3.3 PBS/RPBS use: acne (16%), sinusitis (14%) Private use: travel (74%) Higher use in inner regional areas, and patients with COPD or asthma 50% of prescriptions had repeat (commonly for acne or COPD) 14% private use. Private prescriptions more likely to have longer duration of treatment Azithromycin (restricted benefit) 0.7 PBS/RPBS use: Chlamydia infections (55%); ear, eye, Highest use in Higher use in Western 7% of PBS/RPBS prescriptions and 18% of private prescriptions 42% private use
AURA-2016-First-Australian-Report-on-Antimicrobial-use-and-resistance-in-human-health.docx